Talvey Gets Accelerated Approval for Myeloma Treatment
The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.
Source: curetoday.com
Michael Andreini News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Andreini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Andreini Today - Breaking & Trending Today
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...
Source: prnewswire.com
US FDA approves Johnson & Johnson's blood cancer therapy
(Reuters) -Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer. The therapy, Talvey, belongs to a class of treatments called bispecific antibodies designed to bring a cancer cell and an immune cell together so the body's immune system can kill the cancer. Talvey will be sold at a list price of $45,000 per month, the company told Reuters, adding the price could vary based on a
Source: aol.com
FDA Grants Accelerated Approval to Talquetamab-tgvs for Patients With Heavily Pretreated Multiple Myeloma
Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.
Source: pharmacytimes.com
New blood cancer therapy approved in the U.S. - National
The therapy's approval comes with FDA's "boxed" safety warning, flagging the risk of a type of aggressive immune response and neurologic toxicity.
Source: globalnews.ca